i
i
Up-to-date Information
Up-to-Date Info: To find the latest CDC information on this topic go to: https://www.cdc.gov/coronavirus/2019-nCoV/index.html
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech, Moderna, and Janssen COVID-19 booster doses
-
October 29, 2021
Details:
-
Corporate Authors:
-
Description:A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for booster doses of Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines were presented to the Advisory Committee for Immunization Practices (ACIP) during September–October, 2021. GRADE evidence type indicates the certainty of estimates from the available body of evidence, ranging from type 1 (high certainty) to type 4 (very low certainty).
The policy questions asked whether a booster dose of Pfizer-BioNTech BNT162b2 COVID-19 Vaccine (30 µg, IM), Moderna mRNA-1273 COVID-19 Vaccine (50 µg, IM), or Janssen COVID-19 Ad26.COV2.S Vaccine (5×1010 viral particles, IM) should be recommended for persons aged ≥18 years who completed a COVID-19 vaccine primary series ≥6 months ago (Pfizer-BioNTech, Moderna) or ≥2 months ago (Janssen).
-
Content Notes:Overview -- Methods -- Results -- GRADE Summary.
-
Subjects:
-
Document Type:
-
Name as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: